MediWound Ltd. reported total revenues of $5.84 million for the fourth quarter ended December 31, 2024, an increase from $5.34 million in Q4 2023. The company posted a net loss of $3.91 million, or $0.36 per share, for the quarter, compared to a net loss of $1.74 million, or $0.19 per share, in Q4 2023.
For the full year 2024, total revenues reached $20.22 million, up from $18.69 million in 2023. The full-year net loss widened to $30.22 million, or $3.03 per share, compared to $6.72 million, or $0.75 per share, in 2023. The company projects $24 million in revenue for 2025.
As of December 31, 2024, MediWound held $43.6 million in cash, cash equivalents, and deposits. The company used $22.9 million to fund operations in 2024, including $6.8 million for capital expenditures primarily related to facility scale-up. Strategic collaborations, including a new partnership with Kerecis, were also highlighted.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.